頁籤選單縮合
題名 | 最新偏頭痛治療準則的新觀點=The News from 2015 Acute Treatment of Migraine Guide |
---|---|
作者姓名(中文) | 林嘉慶; 邱惠敏; | 書刊名 | 藥學雜誌 |
卷期 | 31:4=125 2015.12[民104.12] |
頁次 | 頁15-20 |
分類號 | 418.2133 |
關鍵詞 | 偏頭痛; 藥物治療; 治療準則; Migraine; Pharmacotherapy; |
語文 | 中文(Chinese) |
中文摘要 | 偏頭痛屬於高盛行率的疾病。上次美國神經學學會公布偏頭痛急性發作藥物治療 準則是2000年,期間已經過了15年。終於在2015年一月時發布了新的治療準則。相較 於上一份治療準則是由科學證據與專家意見所組成,新準則構成則是完全基於科學證 據,並依照實證醫學的系統性回顧做法,搜尋發表於1998-2013年內與偏頭痛治療相 關的文獻證據,依照各別藥物與安慰劑相比的治療效果分等級:level A 為有效治療, level B 為可能有效的治療,level C 為或許有效的治療。比較兩次的準則,例如口服 Acetaminophen 1000 mg、Diclofenac 50,100 mg, Naproxen 500,550 mg 改列為 level A, 常用的 Ergotamine 1-2 mg 降級為 level C,皮下注射 Octreotide 100 mcg 為可能無效的 治療。據此醫師可以依照新準則與病人個別狀況給予最有效、安全的治療。 |
英文摘要 | Migraine is a highly prevalent disorder. January 21, 2015 The American Headache Society (AHS) has released a new "assessment" of therapies for the acute treatment of migraine - the first update since 2000. While the previous guidelines were based on both scientific evidence and expert opinion, the new guidelines have been put together purely on scientific evidence. An evidence based literature search was performed to identify articles related to acute migraine treatment that were published between 1998 and 2013. By comparing the effectiveness to placebo, the medications are divided into - the level A treatments all having shown effectiveness in rigorous clinical trials. Levels B and C include agents which have not got the same level of evidence - B being probably effective and C being possibly effective." According to the previous and new guideline, we know oral Acetaminophen 1000 mg, Diclofenac 50,100 mg, Naproxen 500,550 mg are prompt to level A, and oral Ergotamine 1~2 mg is shifted to level C,subcutaneous Octreotide 100 mcg is probably not effective. Finally, doctors can take care of patients by following the new guidance. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。